Q-omics provides the consensus-scored TMEM131 profile across patient tissues and cancer cell-line models. TMEM131 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, TMEM131 is differentially expressed in 15, with the highest sampling consensus in COAD. Additionally, TMEM131 protein abundance shows 23,307 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight MESO, COAD, and GBM as cancer lineages where TMEM131 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMEM131 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMEM131 survival associations across molecular data types. TMEM131 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (6) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMEM131 RNA expression–survival associations across cancer types. High TMEM131 expression shows unfavorable associations in MESO, ACC, LGG and LIHC, but favorable associations in KIRC and HNSC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for TMEM131 RNA expression.
This table summarizes TMEM131 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for TMEM131. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMEM131 shows lower tumor expression in COAD and higher tumor expression in HNSC, LIHC, LUSC, LUAD and BRCA. The COAD box plot shows higher TMEM131 RNA expression in normal versus tumor tissue (log2 FC = −1.070, t-test p < 0.001).
This table shows molecular features associated with TMEM131 in patient tissues and cancer cell lines. In patient samples, TMEM131 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, TMEM131 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BLOOD_Leukemia.
